Clio P Mavragani

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/6326539/publications.pdf

Version: 2024-02-01

124 papers	3,890 citations	126907 33 h-index	133252 59 g-index
124 all docs	124 docs citations	124 times ranked	3887 citing authors

#	Article	IF	Citations
1	Subclinical atherosclerosis profiles in rheumatoid arthritis and primary SjÃ¶grenâ€™s syndrome: the impact of BAFF genetic variations. Rheumatology, 2023, 62, 958-968.	1.9	2
2	Sjogrenâ€™s Syndrome: Recent Updates. Journal of Clinical Medicine, 2022, 11, 399.	2.4	9
3	Sjogren's syndrome and lung involvement. Handbook of Systemic Autoimmune Diseases, 2022, , 55-71.	0.1	0
4	Milk Fat Globule Epidermal Growth Factor 8 (MFGE8) Gene Variants in Rheumatoid Arthritis and SjÃ¶grenâ€™s Syndrome. Journal of Clinical Medicine, 2022, 11, 1180.	2.4	2
5	Lupus-like disease and progressive multifocal leukoencephalopathy following etanercept treatment: just a coincidence?. Clinical and Experimental Rheumatology, 2022, 40, 671-672.	0.8	1
6	Hematological Abnormalities in COVID-19 Disease: Association With Type I Interferon Pathway Activation and Disease Outcomes. Frontiers in Medicine, 2022, 9, 850472.	2.6	10
7	Genetic Variants of the BAFF Gene and Risk of Fatigue Among Patients With Primary SjÃ¶grenâ€™s Syndrome. Frontiers in Immunology, 2022, 13, 836824.	4.8	5
8	Vitamin D Deficiency in Primary SjÃ¶grenâ€™s Syndrome: Association with Clinical Manifestations and Immune Activation Markers. Mediterranean Journal of Rheumatology, 2022, 33, 106.	0.8	3
9	COVID-19: Clinical features and outcomes in unvaccinated 2-dose and 3-dose vaccinated against SARS-CoV-2 patients with systemic autoimmune and autoinflammatory rheumatic diseases. Journal of Autoimmunity, 2022, 131, 102846.	6.5	6
10	Osteoprotegerin and MTHFR gene variationsÂinÂrheumatoid arthritis: association with disease susceptibility and markers of subclinical atherosclerosis. Scientific Reports, 2022, 12, .	3.3	6
11	Emerging roles for chemokines and cytokines as orchestrators of immunopathology in SjÃ¶grenâ€™s syndrome. Rheumatology, 2021, 60, 3072-3087.	1.9	36
12	Expression of APOBEC family members as regulators of endogenous retroelements and malignant transformation in systemic autoimmunity. Clinical Immunology, 2021, 223, 108649.	3.2	9
13	B-cell Activating Factor Polymorphisms in Rheumatoid Arthritis-Associated Atherosclerosis. Mediterranean Journal of Rheumatology, 2021, 32, 179.	0.8	0
14	Immune Dysfunction and Drug Targets in Autoinflammatory Syndromes. , 2021, , .		0
15	Leukocyte Immunoglobulin-Like Receptor A3 (LILRA3): A Novel Marker for Lymphoma Development among Patients with Young Onset Sjogrenâ€™s Syndrome. Journal of Clinical Medicine, 2021, 10, 644.	2.4	7
16	Musculoskeletal Manifestations in Sjogrenâ€™s Syndrome: An Orthopedic Point of View. Journal of Clinical Medicine, 2021, 10, 1574.	2.4	4
17	TLR7 Signaling Drives the Development of SjÃ¶grenâ€™s Syndrome. Frontiers in Immunology, 2021, 12, 676010.	4.8	18
18	Lipoprotein-Associated Phospholipase A2: A Novel Contributor in SjÃ¶grenâ€™s Syndrome-Related Lymphoma?. Frontiers in Immunology, 2021, 12, 683623.	4.8	6

#	Article	IF	Citations
19	A biomarker for lymphoma development in Sjogren's syndrome: Salivary gland focus score. Journal of Autoimmunity, 2021, 121, 102648.	6.5	24
20	Scleroderma specific autoantibodies and MS-like manifestations: A novel association?. Autoimmunity Reviews, 2021, 20, 102871.	5.8	0
21	+3179G/A Insulin-Like Growth Factor-1 Receptor Polymorphism: A Novel Susceptibility Contributor in Anti-Ro/SSA Positive Patients with SjÃ¶grenâ€™s Syndrome: Potential Clinical and Pathogenetic Implications. Journal of Clinical Medicine, 2021, 10, 3960.	2.4	5
22	Effective DNA damage response after acute but not chronic immune challenge: SARS-CoV-2 vaccine versus Systemic Lupus Erythematosus. Clinical Immunology, 2021, 229, 108765.	3.2	29
23	Type I interferon detection in autoimmune diseases: challenges and clinical applications. Expert Review of Clinical Immunology, 2021, 17, 883-903.	3.0	6
24	Interferon (IFN)-stimulated gene 15: A novel biomarker for lymphoma development in SjÃ¶gren's syndrome. Journal of Autoimmunity, 2021, 123, 102704.	6.5	9
25	COVID-19 infection among autoimmune rheumatic disease patients: Data from an observational study and literature review. Journal of Autoimmunity, 2021, 123, 102687.	6.5	19
26	Adenosine-to-inosine RNA editing contributes to type I interferon responses in systemic sclerosis. Journal of Autoimmunity, 2021, 125, 102755.	6.5	14
27	Polyarthritis and Psoriasiform Skin Lesions following Pembrolizumab Therapy. Mediterranean Journal of Rheumatology, 2021, 32, 367.	0.8	1
28	Eosinophilic Fasciitis following Checkpoint Inhibitor Therapy with Pembrolizumab. Mediterranean Journal of Rheumatology, 2021, 32, 376.	0.8	4
29	Editorial: Management of SjÃ¶gren's Syndrome. Frontiers in Medicine, 2021, 8, 836182.	2.6	0
30	Combined seronegativity in SjÃ¶gren's syndrome. Clinical and Experimental Rheumatology, 2021, , .	0.8	0
31	Combined seronegativity in SjÃ¶gren's syndrome. Clinical and Experimental Rheumatology, 2021, 39, 80-84.	0.8	8
32	Lupus-like disease and progressive multifocal leukoencephalopathy following etanercept treatment: just a coincidence?. Clinical and Experimental Rheumatology, 2021, , .	0.8	0
33	Drs. Mavragani and Moutsopoulos reply. Journal of Rheumatology, 2020, 47, 158.2-158.	2.0	0
34	Hypertension: An immune related disorder?. Clinical Immunology, 2020, 212, 108247.	3.2	15
35	TREX1 variants in Sjogren's syndrome related lymphomagenesis. Cytokine, 2020, 132, 154781.	3.2	18
36	SjÃ¶gren's syndrome: Old and new therapeutic targets. Journal of Autoimmunity, 2020, 110, 102364.	6.5	79

#	Article	IF	Citations
37	Atherosclerosis: Beyond the lipid storage hypothesis. The role of autoimmunity. European Journal of Clinical Investigation, 2020, 50, e13195.	3.4	28
38	A case of antisynthetase syndrome. Clinical Case Reports (discontinued), 2020, 8, 1586-1587.	0.5	0
39	Association Between DNA Damage Response, Fibrosis and Type I Interferon Signature in Systemic Sclerosis. Frontiers in Immunology, 2020, 11, 582401.	4.8	34
40	Atherosclerosis in SLE: a potential role for serum parathormone levels. Lupus Science and Medicine, 2020, 7, e000393.	2.7	10
41	Type I and II Interferon Signatures Can Predict the Response to Anti-TNF Agents in Inflammatory Bowel Disease Patients: Involvement of the Microbiota. Inflammatory Bowel Diseases, 2020, 26, 1543-1553.	1.9	16
42	Primary SjÃ¶grenâ€™s Syndrome of Early and Late Onset: Distinct Clinical Phenotypes and Lymphoma Development. Frontiers in Immunology, 2020, 11, 594096.	4.8	45
43	Sicca syndrome following immune checkpoint inhibition. Clinical Immunology, 2020, 217, 108497.	3.2	12
44	Clinical Significance of Higher Cutoffs for Myositis Autoantibody Positivity Using the Euroimmun Research Line Blot: Comment on the Article by Mecoli et al. Arthritis and Rheumatology, 2020, 72, 1042-1044.	5.6	5
45	Lymphoma in SjÃ¶grenâ€™s Syndrome: Predictors and Therapeutic Options. Current Treatment Options in Rheumatology, 2020, 6, 1-17.	1.4	12
46	Predicting Lymphoma Development by Exploiting Genetic Variants and Clinical Findings in a Machine Learning-Based Methodology With Ensemble Classifiers in a Cohort of SjÃ¶gren's Syndrome Patients. IEEE Open Journal of Engineering in Medicine and Biology, 2020, 1, 49-56.	2.3	4
47	SjÃ¶grenâ€™s Syndrome. , 2020, , 225-262.		1
48	The Role of Novel Autoantibodies in the Diagnostic Approach and Prognosis of Patients with Raynaudâ€™s Phenomenon. Mediterranean Journal of Rheumatology, 2020, 31, 427.	0.8	0
49	A Training Tool to support the management and diagnosis of SjÃ¶gren's syndrome. Clinical and Experimental Rheumatology, 2020, 38 Suppl 126, 174-179.	0.8	0
50	Myositis autoantibody profiles and their clinical associations in Greek patients with inflammatory myopathies. Clinical Rheumatology, 2019, 38, 125-132.	2.2	35
51	Biologics in SjÃ¶gren's syndrome. Pharmacological Research, 2019, 147, 104389.	7.1	4
52	Primary versus Secondary SjÃ¶gren Syndrome: Is It Time To Reconsider These Terms?. Journal of Rheumatology, 2019, 46, 665-666.	2.0	38
53	Independent association of low IFNÎ»1 gene expression and type I IFN score/IFNÎ»1 ratio with obstetric manifestations and triple antiphospholipid antibody positivity in primary antiphospholipid syndrome. Clinical Immunology, 2019, 209, 108265.	3.2	13
54	Genetic contributors and soluble mediators in prediction of autoimmune comorbidity. Journal of Autoimmunity, 2019, 104, 102317.	6.5	15

#	Article	IF	Citations
55	AB0183â€…THE ROLE OF THE PHOSPHOLIPASE LP-PLA2 ACTIVITY IN SJOGRENâ€™S SYNDROME RELATED LYMPHOMAGENESIS: A NEW SERUM BIOMARKER?. , 2019, , .		1
56	THU0204â€…ASSOCIATION OF LILRA3 GENE WITH LYMPHOMAGENESIS RISK IN YOUNG SS PATIENTS. , 2019, , .		2
57	THU0228â€…EXPRESSION OF APOBEC FAMILY MEMBERS AS REGULATORS OF ENDOGENOUS RETROELEMENTS AND MALIGNANCY IN SYSTEMIC LUPUS ERYTHEMATOSUS AND SJÃ–GRENâ€™S SYNDROME. , 2019, , .		1
58	B cells and atherosclerosis in systemic lupus erythematosus. Expert Review of Clinical Immunology, 2019, 15, 417-429.	3.0	8
59	Type I Interferonopathies: From Pathophysiology to Clinical Expression. , 2019, , 125-145.		1
60	Type I interferon signature in SjÃ¶gren's syndrome: pathophysiological and clinical implications. Clinical and Experimental Rheumatology, 2019, 37 Suppl 118, 185-191.	0.8	16
61	Contribution of MTHFR gene variants in lupus related subclinical atherosclerosis. Clinical Immunology, 2018, 193, 110-117.	3.2	25
62	Low disease activityâ€”irrespective of serologic status at baselineâ€”associated with reduction of corticosteroid dose and number of flares in patients with systemic lupus erythematosus treated with belimumab: A real-life observational study. Seminars in Arthritis and Rheumatism, 2018, 48, 467-474.	3.4	59
63	Defective regulation of L1 endogenous retroelements in primary Sjogren's syndrome and systemic lupus erythematosus: Role of methylating enzymes. Journal of Autoimmunity, 2018, 88, 75-82.	6.5	65
64	TNFAIP3 F127C Coding Variation in Greek Primary Sjogrenâ€™s Syndrome Patients. Journal of Immunology Research, 2018, 2018, 1-8.	2.2	24
65	B-cell activating factor and related genetic variants in lupus related atherosclerosis. Journal of Autoimmunity, 2018, 92, 87-92.	6.5	51
66	Anxiety and Extraversion in Lupus-Related Atherosclerosis. Frontiers in Psychiatry, 2018, 9, 246.	2.6	10
67	Tongue Atrophy in SjÃ¶gren Syndrome Patients with Mucosa-associated Lymphoid Tissue Lymphoma: Autoimmune Epithelitis beyond the Epithelial Cells of Salivary Glands?. Journal of Rheumatology, 2018, 45, 1565-1571.	2.0	11
68	Multicenter Cross-sectional Study of Patients with Rheumatoid Arthritis in Greece: Results from a cohort of 2.491 patients. Mediterranean Journal of Rheumatology, 2018, 29, 27-37.	0.8	13
69	Study of the incidence of osteoporosis in patients with SjÃ¶grenâ€™s syndrome (pSS) and investigation of activation of the RANKL / RANK and osteoprotegerin (OPG) system. Mediterranean Journal of Rheumatology, 2018, 29, 224-227.	0.8	4
70	Psychological comorbidities associated with subclinical atherosclerosis in Greek patients with primary SjÃ¶gren's syndrome: a potential contribution of sleep impairment. Clinical and Experimental Rheumatology, 2018, 36 Suppl 112, 68-72.	0.8	2
71	Prevalence and spectrum of symptomatic pulmonary involvement in primary SjÃ¶gren's syndrome. Clinical and Experimental Rheumatology, 2018, 36 Suppl 112, 94-101.	0.8	14
72	Autoantibodies to ox-LDL in SjÃ¶gren's syndrome: are they atheroprotective?. Clinical and Experimental Rheumatology, 2018, 36 Suppl 112, 61-67.	0.8	5

#	Article	IF	Citations
73	Mechanisms and New Strategies for Primary SjÃ¶gren's Syndrome. Annual Review of Medicine, 2017, 68, 331-343.	12.2	68
74	Cardiovascular disease in systemic lupus erythematosus: A comprehensive update. Journal of Autoimmunity, 2017, 82, 1-12.	6.5	132
75	07.13â€…A case of sting-associated vasculopathy with onset in infancy (savi) in a young adult male with a novel tmem173 gene mutation. , 2017, , .		0
76	Antibodies against citrullinated alpha enolase peptides in primary Sjogren's syndrome. Clinical Immunology, 2017, 183, 300-303.	3.2	21
77	Type I interferonopathy in a young adult. Rheumatology, 2017, 56, 2241-2243.	1.9	17
78	MTHFR gene variants and non-MALT lymphoma development in primary Sjogrenâ€™s syndrome. Scientific Reports, 2017, 7, 7354.	3.3	28
79	Stress and Disease Onset in Antineutrophil Cytoplasmic Antibody-Associated Vasculitis. Frontiers in Psychiatry, 2017, 8, 286.	2.6	6
80	Type I interferon signature may influence the effect of belimumab on immunoglobulin levels, including rheumatoid factor in SjÃ¶gren's syndrome. Clinical and Experimental Rheumatology, 2017, 35, 719-720.	0.8	3
81	Expression of Long Interspersed Nuclear Element 1 Retroelements and Induction of Type I Interferon in Patients With Systemic Autoimmune Disease. Arthritis and Rheumatology, 2016, 68, 2686-2696.	5.6	149
82	Predictors of renal histopathology in antineutrophil cytoplasmic antibody associated glomerulonephritis. Journal of Autoimmunity, 2016, 72, 57-64.	6.5	6
83	Etiopathogenesis of Sjogrenâ€™s Syndrome. Rare Diseases of the Immune System, 2016, , 279-292.	0.1	0
84	Fatigue in Primary SjÃ¶gren's Syndrome: Clinical, Laboratory, Psychometric, and Biologic Associations. Arthritis Care and Research, 2016, 68, 123-131.	3.4	64
85	Increased frequency of the PTPN22W* variant in primary Sjogren's Syndrome: Association with low type I IFN scores. Clinical Immunology, 2016, 173, 157-160.	3.2	24
86	Predicting the risk for lymphoma development in Sjogren syndrome. Medicine (United States), 2016, 95, e3766.	1.0	137
87	A BAFF Receptor His159Tyr Mutation in SjÃ¶gren's Syndromeâ€“Related Lymphoproliferation. Arthritis and Rheumatology, 2015, 67, 2732-2741.	5.6	60
88	Clinical and Laboratory Predictors of Distinct Histopathogical Features of Lupus Nephritis. Medicine (United States), 2015, 94, e829.	1.0	42
89	Contribution of Genetic Factors to SjÃ¶grenâ€™s Syndrome and SjÃ¶grenâ€™s Syndrome Related Lymphomagenesis. Journal of Immunology Research, 2015, 2015, 1-12.	2.2	31
90	Subclinical atherosclerosis and impaired bone health in patients with primary Sjogrenâ€™s syndrome: prevalence, clinical and laboratory associations. Arthritis Research and Therapy, 2015, 17, 99.	3.5	64

#	Article	IF	Citations
91	SjÃ¶grenâ€™s Syndrome. , 2015, , 419-428.		0
92	Type I and II interferon signatures in Sjogren's syndrome pathogenesis: Contributions in distinct clinical phenotypes and Sjogren's related lymphomagenesis. Journal of Autoimmunity, 2015, 63, 47-58.	6.5	215
93	Predicting the Outcome of Sjogrenâ€™s Syndrome-Associated Non-Hodgkinâ€™s Lymphoma Patients. PLoS ONE, 2015, 10, e0116189.	2.5	77
94	Adverse events and infections in patients with rheumatoid arthritis treated with conventional drugs or biologic agents: a real world study. Clinical and Experimental Rheumatology, 2015, 33, 216-24.	0.8	32
95	Elevated IgG4 Serum Levels Among Primary SjÃ¶gren's Syndrome Patients: Do They Unmask Underlying IgG4â€Related Disease?. Arthritis Care and Research, 2014, 66, 773-777.	3.4	42
96	SjÃ¶gren's Syndrome. Annual Review of Pathology: Mechanisms of Disease, 2014, 9, 273-285.	22.4	198
97	B-cell activating factor genetic variants in lymphomagenesis associated with primary Sjogren's syndrome. Journal of Autoimmunity, 2014, 51, 89-98.	6.5	99
98	SjÃ¶grenâ€™s Syndrome. , 2014, , 495-510.		3
99	SjÃ¶gren syndrome. Cmaj, 2014, 186, E579-E586.	2.0	135
100	SjÃ¶grenâ€™s Syndrome. , 2014, , 1069-1075.		0
101	Treatment of dry eyes in SjÃ¶gren's syndrome: the role of autologous blood serum. Expert Opinion on Orphan Drugs, 2013, 1, 445-456.	0.8	1
102	Increased Serum Type I Interferon Activity in Organ-Specific Autoimmune Disorders: Clinical, Imaging, and Serological Associations. Frontiers in Immunology, 2013, 4, 238.	4.8	17
103	New advances in the classification, pathogenesis and treatment of Sjogren's syndrome. Current Opinion in Rheumatology, 2013, 25, 623-629.	4.3	48
104	Linear IgA dermatosis in a patient with primary Sjogren's syndrome. Rheumatology, 2013, 52, 403-404.	1.9	6
105	Adult-Onset Stillâ€™s Disease: From Pathophysiology to Targeted Therapies. International Journal of Inflammation, 2012, 2012, 1-10.	1.5	48
106	Brief Report: Adrenal autoimmunity in primary SjÃ¶gren's syndrome. Arthritis and Rheumatism, 2012, 64, 4066-4071.	6.7	16
107	Endocrine alterations in primary Sjogren's syndrome: An overview. Journal of Autoimmunity, 2012, 39, 354-358.	6.5	64
108	Lymphotoxin-beta receptor blockade reduces CXCL13 in lacrimal glands and improves corneal integrity in the NOD model of SjÃ¶gren's syndrome. Arthritis Research and Therapy, 2011, 13, R182.	3.5	71

#	Article	IF	Citations
109	Activation of the type I interferon pathway in primary SjÃ¶gren's syndrome. Current Opinion in Rheumatology, 2011, 23, 459-464.	4.3	46
110	The geoepidemiology of SjÃ¶gren's syndrome. Autoimmunity Reviews, 2010, 9, A305-A310.	5.8	246
111	Association of the response to tumor necrosis factor antagonists with plasma type I interferon activity and interferonâ€Î²/Î± ratios in rheumatoid arthritis patients: A post hoc analysis of a predominantly Hispanic cohort. Arthritis and Rheumatism, 2010, 62, 392-401.	6.7	77
112	Psychopathological and personality features in primary Sjogren's syndrome--associations with autoantibodies to neuropeptides. Rheumatology, 2010, 49, 1762-1769.	1.9	43
113	Activation of the type I interferon pathway in primary Sjogrenâ€™s syndrome. Journal of Autoimmunity, 2010, 35, 225-231.	6.5	165
114	Increased Prevalence of Antibodies to Thyroid Peroxidase in Dry Eyes and Mouth Syndrome or Sicca Asthenia Polyalgia Syndrome. Journal of Rheumatology, 2009, 36, 1626-1630.	2.0	17
115	Activation of type I interferon in systemic lupus erythematosus. Expert Review of Clinical Immunology, 2007, 3, 579-588.	3.0	16
116	Augmented interferonâ€Î± pathway activation in patients with SjÃ¶gren's syndrome treated with etanercept. Arthritis and Rheumatism, 2007, 56, 3995-4004.	6.7	140
117	Retroperitoneal fibrosis and c-ANCA positivity. Clinical Rheumatology, 2007, 26, 115-116.	2.2	11
118	Conventional Therapy of Sjogrenâ€™s Syndrome. Clinical Reviews in Allergy and Immunology, 2007, 32, 284-291.	6.5	61
119	Ill-defined neurological syndromes with autoimmune background: a diagnostic challenge. Journal of Rheumatology, 2007, 34, 341-5.	2.0	6
120	The management of SjÃ¶gren's syndrome. Nature Clinical Practice Rheumatology, 2006, 2, 252-261.	3.2	110
121	Is polydipsia sometimes the cause of oxcarbazepine-induced hyponatremia?. European Journal of Internal Medicine, 2005, 16, 296-297.	2.2	11
122	Cutaneous ulcers: An unusual manifestation of inherited thrombophilia. American Journal of Hematology, 2004, 76, 139-142.	4.1	6
123	Pure red cell aplasia in a SjÃ¶gren's syndrome/lupus erythematosus overlap patient. American Journal of Hematology, 2003, 72, 259-262.	4.1	9
124	SjÃ¶grenâ€™s Syndrome: Autoantibodies to Cellular Antigens. International Archives of Allergy and Immunology, 2000, 123, 46-57.	2.1	63